Article

Type II JAK2 Inhibitor CHZ‐868 and HSP90 Inhibitors Are Potent towards the Ruxolitinib Resistant JAK2 Variants in JAK2 Driven Myeloproliferative Neoplasms

2024-01-03

Abstract excerpt

Ruxolitinib has been approved by FDA for the treatment of myeloproliferative neoplasms such as polycythemia vera and idiopathic myelofibrosis. Although ruxolitinib has been in the clinic for more than ten years, surprisingly, no JAK2 drug resistant mutations have been identified in patients. At the moment, it is not clear whether the absence of JAK2 mutations in MPN patients is due to a lack of JAK2 addiction or r...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f8a8d637-137f-5157-ba34-f752d964e079
DOI: 10.20944/preprints202401.0265.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Type II JAK2 Inhibitor CHZ‐868 and HSP90 Inhibitors Are Potent towards the Ruxolitinib Resistant JAK2 Variants in JAK2 Driven Myeloproliferative NeoplasmsDOI 10.20944/preprints202401.0265.v1Read

Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.Semantic proximity Read

Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.Semantic proximity Read

Next-Generation JAK2 Inhibitors for the Treatment of Myeloproliferative Neoplasms: Lessons from Structure-Based Drug Discovery Approaches.Semantic proximity Read

New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation.Semantic proximity Read

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemiaSemantic proximity Read

Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase InhibitorSemantic proximity Read

The resistance tetrad: amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles.Semantic proximity Read

JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasmsSemantic proximity Read

Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.Semantic proximity Read

A method for screening and validation of resistant mutations against kinase inhibitors.Semantic proximity Read

Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?Semantic proximity Read

Effects of JAK2 V556F mutation on the JAK2's activity, structural stability and the transformation of Ba/F3 cells.Semantic proximity Read